ReviewInternational journal of nanomedicine2026
Nanomaterials in Targeted Immunotherapy for Chronic Spontaneous Urticaria: Focusing on Immune Cell Modulation and Precision Treatment.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic spontaneous urticaria (CSU) is an immune-mediated skin disorder marked by recurrent hives and angioedema, affecting a large proportion of the global population. Traditional immunotherapy often fails, particularly in difficult-to-treat cases, highlighting the need for more precise, immune cell-targeted treatments. Nanomaterials offer unique advantages, such as size tuning, surface functionalization, and controlled release, allowing precise targeting of immune cell receptors. This is crucial for enhancing treatment efficacy and minimizing systemic side effects. This review explores the potential of nanomaterials in CSU immunotherapy, focusing on their ability to modulate immune cells-such as mast cells, eosinophils, basophils, and T lymphocytes-to restore immune balance and alleviate symptoms. However, challenges remain in the clinical application of nanomaterials, including concerns about immunotoxicity, long-term safety, and the need for stronger evidence of efficacy in human trials. Additionally, while AI in optimizing nanomaterial design shows promise, it is still in early development and requires further exploration to enhance its practical applications. Current nanomaterial applications in allergic diseases, such as food allergies and asthma, show promise but differ from CSU in immune mechanisms like mast cell-eosinophil interactions and neuroimmune pathways. This approach is novel in that nanomaterials could provide a more precise, targeted solution for CSU, overcoming the limitations of current therapies. Future research should focus on optimizing nanomaterial formulations, integrating multi-omics analyses, and developing AI-driven strategies for personalized treatment. These advances could pave the way for safer, more effective immunotherapies in CSU and other immune-mediated diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.